A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: A need for more rigorous testing of neuroprotective agents in animal models of stroke

Experimental Neurology

Volumn 205, Issue 1, 2007, Pages 20-25

  Savitz, Sean I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM; DRUG VEHICLE; NEUROPROTECTIVE AGENT;

ACUTE DISEASE; ANIMAL BEHAVIOR; BRAIN EMBOLISM; BRAIN ISCHEMIA; CLINICAL STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MEDICAL LITERATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; BENZENESULFONATES; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INTRACRANIAL EMBOLISM; NEUROPROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 34247263212     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.03.003     Document Type: Review

References (21)

1. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., and Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 (1986) 472-476
3. Ding Y., Zhou Y., Lai Q., Li J., Gordon V., and Diaz F.G. Long-term neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment. Brain Res. 915 (2001) 210-217
4. Gladstone D.J., Black S.E., and Hakim A.M. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002) 2123-2136
5. Hankey G.J. Neuroprotection for acute ischaemic stroke: hope reignited. Lancet Neurol. 5 (2006) 287-288
6. Hess D.C. NXY-059: a hopeful sign in the treatment of stroke. Stroke 37 (2006) 2649-2650
7. Hill M.D. Stroke: the dashed hopes of neuroprotection. Lancet Neurol. 6 (2007) 2-3
8. Koziol J.A., and Feng A.C. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke 37 (2006) 2644-2647
9. Kuroda S., Tsuchidate R., Smith M.L., Maples K.R., and Siesjo B.K. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 19 (1999) 778-787
10. Lapchak P.A., Araujo D.M., Song D., Wei J., and Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33 (2002) 1411-1415
11. Lees K.R. Comparison of neuroprotective data for NXY-09 in animal models with the STAIR criteria. Cerebrovasc. Dis. 11 (2001) 77
12. Lees K.R., Zivin J.A., Ashwood T., Davalos A., Davis S.M., Diener H.C., Grotta J., Lyden P., Shuaib A., Hardemark H.G., and Wasiewski W.W. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354 (2006) 588-600
13. Marshall J.W., Duffin K.J., Green A.R., and Ridley R.M. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32 (2001) 190-198
14. Marshall J.W., Cummings R.M., Bowes L.J., Ridley R.M., and Green A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34 (2003) 2228-2233
15. O'Collins V.E., Macleod M.R., Donnan G.A., Horky L.L., van der Worp B.H., and Howells D.W. 1026 experimental treatments in acute stroke. Ann. Neurol. 59 (2006) 467-477
16. Shuaib A., L.K., Grotta J., et al. SAINT II: results of the second randomized, multicenter, placebo-controlled, double-blind study of NXY-059 treatment in patients with acute ischemic stroke. Stroke (abstract) 38 (2007) 471
17. Sydserff S.G., Borelli A.R., Green A.R., and Cross A.J. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol. 135 (2002) 103-112
18. Takeshima R., Kirsch J.R., Koehler R.C., and Traystman R.J. Tirilazad treatment does not decrease early brain injury after transient focal ischemia in cats. Stroke 25 (1994) 670-676
19. Wang C.X., and Shuaib A. NXY-059: a neuroprotective agent in acute stroke. Int. J. Clin. Pract. 58 (2004) 964-969
20. Yoshimoto T., Kristian T., Hu B., Ouyang Y.B., and Siesjo B.K. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res. 932 (2002) 99-109
21. Zhao Z., Cheng M., Maples K.R., Ma J.Y., and Buchan A.M. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res. 909 (2001) 46-50